ImPact Biotech announced updated Phase 3 ENLIGHTED trial results showing 70% complete response in patients with low-grade upper tract urothelial carcinoma (UTUC) treated with Padeliporfin VTP. The treatment demonstrated durable effects, with 85.7% of patients maintaining complete response for at least 12 months, and a median response duration of nearly 24 months. The therapy was well-tolerated with mostly mild side effects. ImPact plans regulatory submission in 2027 and is exploring commercialization opportunities, highlighting Padeliporfin VTP as a promising minimally invasive option for UTUC patients.
nVent Electric plc announced a quarterly cash dividend of $0.21 per ordinary share, payable on August 7, 2026, to shareholders recorded by July 24, 2026. This dividend reflects nVent's ongoing commitment to returning value to shareholders. The compan...
OpenAI is consolidating its core AI products—ChatGPT, Codex, and its developer API—into a single product team to sharpen focus ahead of a potential IPO later this year. Greg Brockman, previously interim product lead, is now permanently in charge of p...
The TCW Strategic Income Fund (TSI) primarily invests in bonds despite its hybrid strategy claim, which limits its ability to protect against inflation. It offers a competitive 7.45% yield compared to indices but underperforms peer multi-sector funds...
NextEra Energy and Dominion Energy are in talks to merge in a deal valued around $400 billion, creating one of the largest utility companies in the U.S. This merger aims to address the rapidly growing electricity demand driven by AI data centers, ind...
The Advent Convertible and Income Fund (AVK) maintains a buy rating due to its attractive 8.32% discount to net asset value (NAV) and a strong 10.9% dividend yield. The fund's strategy combines convertible securities, high-yield debt, and equities, f...
